Published in Retrovirology on May 10, 2012
Evolution of foamy viruses: the most ancient of all retroviruses. Viruses (2013) 0.89
Prototype foamy virus protease activity is essential for intraparticle reverse transcription initiation but not absolutely required for uncoating upon host cell entry. J Virol (2013) 0.89
Foamy virus assembly with emphasis on pol encapsidation. Viruses (2013) 0.82
Expression of prototype foamy virus pol as a Gag-Pol fusion protein does not change the timing of reverse transcription. J Virol (2012) 0.77
Foamy virus Gag p71-p68 cleavage is required for template switch of the reverse transcriptase. J Virol (2013) 0.76
Mutagenesis of N-terminal residues of feline foamy virus Gag reveals entirely distinct functions during capsid formation, particle assembly, Gag processing and budding. Retrovirology (2016) 0.75
Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses. Science (1996) 3.25
Foamy virus reverse transcriptase is expressed independently from the Gag protein. Proc Natl Acad Sci U S A (1996) 2.22
The roles of Pol and Env in the assembly pathway of human foamy virus. J Virol (1998) 1.82
Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein. J Virol (1995) 1.81
The human foamy virus pol gene is expressed as a Pro-Pol polyprotein and not as a Gag-Pol fusion protein. J Virol (1996) 1.74
Improved primate foamy virus vectors and packaging constructs. J Virol (2002) 1.65
Carboxy-terminal cleavage of the human foamy virus Gag precursor molecule is an essential step in the viral life cycle. J Virol (1997) 1.57
Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors. J Virol (1998) 1.46
Foamy virus biology and its application for vector development. Viruses (2011) 1.38
Primate foamy virus Pol proteins are imported into the nucleus. J Gen Virol (2000) 1.37
Characterization of the spliced pol transcript of feline foamy virus: the splice acceptor site of the pol transcript is located in gag of foamy viruses. J Virol (1996) 1.35
Analysis of prototype foamy virus particle-host cell interaction with autofluorescent retroviral particles. Retrovirology (2010) 1.32
Molecular characterization of proteolytic processing of the Pol proteins of human foamy virus reveals novel features of the viral protease. J Virol (1998) 1.24
Pregenomic RNA is required for efficient incorporation of pol polyprotein into foamy virus capsids. J Virol (2002) 1.22
RNA and protein requirements for incorporation of the Pol protein into foamy virus particles. J Virol (2005) 1.20
Characterization of prototype foamy virus gag late assembly domain motifs and their role in particle egress and infectivity. J Virol (2005) 1.18
Novel functions of prototype foamy virus Gag glycine- arginine-rich boxes in reverse transcription and particle morphogenesis. J Virol (2010) 1.17
Foamy virus transactivation and gene expression. Curr Top Microbiol Immunol (2003) 1.10
The solution structure of the simian foamy virus protease reveals a monomeric protein. J Mol Biol (2008) 1.03
Regulation of foamy virus protease activity by viral RNA: a novel and unique mechanism among retroviruses. J Virol (2011) 1.03
Foamy virus nuclear RNA export is distinct from that of other retroviruses. J Virol (2010) 0.98
Orthoretroviral-like prototype foamy virus Gag-Pol expression is compatible with viral replication. Retrovirology (2011) 0.96
AZT resistance of simian foamy virus reverse transcriptase is based on the excision of AZTMP in the presence of ATP. Nucleic Acids Res (2007) 0.95
Biophysical and enzymatic properties of the simian and prototype foamy virus reverse transcriptases. Retrovirology (2010) 0.95
Formation of transient dimers by a retroviral protease. Biochem J (2010) 0.89
Foamy retrovirus integrase contains a Pol dimerization domain required for protease activation. J Virol (2010) 0.87
Complex effects of foamy virus central purine-rich regions on viral replication. Virology (2008) 0.85
A peptide inhibitor of HIV-1 assembly in vitro. Nat Struct Mol Biol (2005) 2.21
The Mason-Pfizer monkey virus PPPY and PSAP motifs both contribute to virus release. J Virol (2003) 2.19
Major biological obstacles for persistent cell-based regeneration of articular cartilage. Arthritis Res Ther (2007) 1.85
Improved primate foamy virus vectors and packaging constructs. J Virol (2002) 1.65
Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34+ cord blood cells. Hum Gene Ther (2003) 1.58
Real-time PCR for diagnosis of human bocavirus infections and phylogenetic analysis. J Clin Microbiol (2007) 1.52
HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high. PLoS One (2011) 1.45
Evidence of recombination in the norovirus capsid gene. J Virol (2005) 1.41
Foamy virus biology and its application for vector development. Viruses (2011) 1.38
A simple and rapid single-step multiplex RT-PCR to detect Norovirus, Astrovirus and Adenovirus in clinical stool samples. J Virol Methods (2004) 1.38
Hypertrophy is induced during the in vitro chondrogenic differentiation of human mesenchymal stem cells by bone morphogenetic protein-2 and bone morphogenetic protein-4 gene transfer. Arthritis Res Ther (2009) 1.34
Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin Diagn Lab Immunol (2003) 1.28
Genome-wide mapping of foamy virus vector integrations into a human cell line. J Gen Virol (2006) 1.28
Feline foamy virus genome and replication strategy. J Virol (2003) 1.25
Phylogenetic diversity and low level antiretroviral resistance mutations in HIV type 1 treatment-naive patients from Cape Town, South Africa. AIDS Res Hum Retroviruses (2008) 1.23
Pregenomic RNA is required for efficient incorporation of pol polyprotein into foamy virus capsids. J Virol (2002) 1.22
RNA and protein requirements for incorporation of the Pol protein into foamy virus particles. J Virol (2005) 1.20
The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent. Protein Expr Purif (2006) 1.19
Characterization of prototype foamy virus gag late assembly domain motifs and their role in particle egress and infectivity. J Virol (2005) 1.18
Foamy virus envelope glycoprotein-mediated entry involves a pH-dependent fusion process. J Virol (2003) 1.16
Prototype foamy virus envelope glycoprotein leader peptide processing is mediated by a furin-like cellular protease, but cleavage is not essential for viral infectivity. J Virol (2004) 1.14
From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease. Proc Natl Acad Sci U S A (2005) 1.11
Heparan sulfate is an attachment factor for foamy virus entry. J Virol (2012) 1.07
The solution structure of the simian foamy virus protease reveals a monomeric protein. J Mol Biol (2008) 1.03
Regulation of foamy virus protease activity by viral RNA: a novel and unique mechanism among retroviruses. J Virol (2011) 1.03
Structure-activity relationships of flavonoid-induced cytotoxicity on human leukemia cells. Arch Biochem Biophys (2007) 1.00
Foamy virus nuclear RNA export is distinct from that of other retroviruses. J Virol (2010) 0.98
RNA-binding specificity of E. coli NusA. Nucleic Acids Res (2009) 0.97
The complete nucleotide sequence of a New World simian foamy virus. Virology (2007) 0.97
Biophysical and enzymatic properties of the simian and prototype foamy virus reverse transcriptases. Retrovirology (2010) 0.95
AZT resistance of simian foamy virus reverse transcriptase is based on the excision of AZTMP in the presence of ATP. Nucleic Acids Res (2007) 0.95
Crystal structure of the human transcription elongation factor DSIF hSpt4 subunit in complex with the hSpt5 dimerization interface. Biochem J (2009) 0.95
CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells. J Biol Chem (2004) 0.94
N-terminal Gag domain required for foamy virus particle assembly and export. J Virol (2005) 0.94
Structural studies on the RNA-recognition motif of NELF E, a cellular negative transcription elongation factor involved in the regulation of HIV transcription. Biochem J (2006) 0.93
Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease. Antimicrob Agents Chemother (2012) 0.93
Noncanonical microRNA (miRNA) biogenesis gives rise to retroviral mimics of lymphoproliferative and immunosuppressive host miRNAs. MBio (2014) 0.92
Accuracy estimation of foamy virus genome copying. Retrovirology (2009) 0.92
Generation of an improved foamy virus vector by dissection of cis-acting sequences. J Gen Virol (2009) 0.90
Interaction of the intrinsically unstructured phage lambda N Protein with Escherichia coli NusA. Biochemistry (2006) 0.90
High-efficiency gene transfer into cultured embryonic motoneurons using recombinant lentiviruses. Histochem Cell Biol (2006) 0.89
Subcellular localization and integration activities of rous sarcoma virus reverse transcriptase. J Virol (2002) 0.89
Evolution of foamy viruses: the most ancient of all retroviruses. Viruses (2013) 0.89
Formation of transient dimers by a retroviral protease. Biochem J (2010) 0.89
Identification of protein phosphorylation sites by combination of elastase digestion, immobilized metal affinity chromatography, and quadrupole-time of flight tandem mass spectrometry. Proteomics (2002) 0.88
High-yield expression and purification of isotopically labeled norcoclaurine synthase, a Bet v 1-homologous enzyme, from Thalictrum flavum for NMR studies. Protein Expr Purif (2007) 0.87
Determinants of foamy virus envelope glycoprotein mediated resistance to superinfection. Virology (2003) 0.87
Retrotransposition and cell-to-cell transfer of foamy viruses. J Virol (2003) 0.86
Determination of the relative amounts of Gag and Pol proteins in foamy virus particles. Retrovirology (2005) 0.86
A complex immunodeficiency is based on U1 snRNP-mediated poly(A) site suppression. EMBO J (2012) 0.86
Analysis and function of prototype foamy virus envelope N glycosylation. J Virol (2005) 0.85
Complex effects of foamy virus central purine-rich regions on viral replication. Virology (2008) 0.85
Characterisation of a chikungunya virus from a German patient returning from Mauritius and development of a serological test. Med Microbiol Immunol (2008) 0.83
AZT-resistant foamy virus. Virology (2007) 0.83
NELF-E RRM undergoes major structural changes in flexible protein regions on target RNA binding. Biochemistry (2008) 0.83
Foamy virus integration. J Virol (2004) 0.83
An autoinhibited state in the structure of Thermotoga maritima NusG. Structure (2013) 0.81
Dual activity of phosphorothioate CpG oligodeoxynucleotides on HIV: reactivation of latent provirus and inhibition of productive infection in human T cells. Ann N Y Acad Sci (2006) 0.81
The solution structure of the prototype foamy virus RNase H domain indicates an important role of the basic loop in substrate binding. Retrovirology (2012) 0.81
Insights into the structure and activity of prototype foamy virus RNase H. Retrovirology (2012) 0.80
Acetylation of the foamy virus transactivator Tas by PCAF augments promoter-binding affinity and virus transcription. J Gen Virol (2007) 0.80
Regulation of retroviral polyadenylation. Adv Virus Res (2013) 0.79
Structural requirements for enzymatic activities of foamy virus protease-reverse transcriptase. Proteins (2013) 0.79
Molecular analysis of HIV type 1 vif sequences from Cape Town, South Africa. AIDS Res Hum Retroviruses (2008) 0.79
U1snRNP-mediated suppression of polyadenylation in conjunction with the RNA structure controls poly (A) site selection in foamy viruses. Retrovirology (2013) 0.79
Basic residues in the foamy virus Gag protein. J Virol (2011) 0.79
Ex vivo gene delivery to synovium using foamy viral vectors. J Gene Med (2014) 0.78
HIV patients treated with low-dose prednisolone exhibit lower immune activation than untreated patients. BMC Infect Dis (2012) 0.78
Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy. Bioorg Med Chem (2012) 0.77
Obituary: Axel Rethwilm (1959-2014). Retrovirology (2014) 0.77
Caspase inhibition in apoptotic T cells triggers necrotic cell death depending on the cell type and the proapoptotic stimulus. J Cell Biochem (2006) 0.77
Complete nucleotide sequence and evolutionary analysis of a gorilla foamy virus. J Gen Virol (2010) 0.77
The small hSpt4 subunit of the human transcription elongation factor DSIF is a Zn-finger protein with alpha/beta type topology. Biochem Biophys Res Commun (2008) 0.77
Construction of a high titer infectious HIV-1 subtype C proviral clone from South Africa. Viruses (2012) 0.77
Foamy virus Gag p71-p68 cleavage is required for template switch of the reverse transcriptase. J Virol (2013) 0.76
Genotypic resistance testing in HIV by arrayed primer extension. Anal Bioanal Chem (2008) 0.76
An inducible Tet-Off-H2B-GFP lentiviral reporter vector for detection and in vivo isolation of label-retaining cells. Exp Cell Res (2010) 0.76
Experimental therapy of allogeneic solid tumors induced in athymic mice with suicide gene-transducing replication-competent foamy virus vectors. Cancer Gene Ther (2005) 0.76
Inducible APOBEC3G-Vif double stable cell line as a high-throughput screening platform to identify antiviral compounds. Antimicrob Agents Chemother (2009) 0.76
AZT resistance alters enzymatic properties and creates an ATP-binding site in SFVmac reverse transcriptase. Retrovirology (2015) 0.76
Assessing the risk of transmission of viral diseases in flooded areas: viral load of the River Elbe in Dresden during the flood of August 2002. Intervirology (2006) 0.76